CAR T therapy for B-cell ALL after initial treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests whether a special immune cell therapy (brexucabtagene autoleucel, or CAR T therapy) can help people with B-cell acute lymphocytic leukemia (ALL) after reducing the number of leukemia cells with a chemo-immunotherapy combination. It is for patients whose cancer has returned or is hard to treat, or for those newly diagnosed with a high-risk form of ALL.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have either relapsed/refractory B-cell ALL OR newly diagnosed high-risk B-cell ALL (with specific genetic changes like KMT2A rearranged or Philadelphia-like).
- Your leukemia cells must have the CD19 protein (more than 50% positive).
- You are active enough to be out of bed at least half the day (performance status 0-2).
- You have adequate liver and kidney function, and any chronic infections (like hepatitis or HIV) are under control with treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR T-cell therapy (obecabtagene autoleucel) given as a consolidation treatment after initial remission to prevent relapse in people with high-risk B-cell ALL. It's for patients who have achieved first remission but still have high-risk features in their leukemia.
This trial tests a new CAR T-cell therapy (KITE-753) for adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or not responded to previous treatments. The therapy uses your own immune cells, modified to find and attack leukemia cells, and may offer a new option when standard treatments have stopped working.
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
This trial studies a type of immune therapy (CAR T-cells) for people whose leukemia or lymphoma has come back or did not respond after at least two treatment attempts. It aims to improve outcomes in carefully selected patients who can safely receive the treatment.
This trial tests a new type of CAR T-cell therapy—a treatment that uses your own immune cells engineered to fight leukemia cells. It is designed for patients with B-cell acute lymphoblastic leukemia (ALL) that has come back or stopped responding to standard treatments, and whose leukemia cells have a specific marker called TSLPR.
Hear when a new Relapsed/Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.